Who
David Hallal
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Scholar Rock Holding; Chief Executive Officer, Kalaris Therapeutics; Director, iTeos Therapeutics; Director, Seer; CEO, Alexion Pharmaceuticals.
In numbers
- Trades disclosed
- 263
- Buys
- 0
- Sells
- 80
- Bought
- $0
- Sold
- $71.5M
- Companies
- 5
- Companies where not an officer
- 2
- First trade
- 11 Jun 2009
- Last trade
- 21 Sep 2026
- Last filed
- 23 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 21 Sep 2026filed 23 Sep 2026 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Code G | —36,652 at $0.00 | filing |
| 21 Sep 2026filed 23 Sep 2026 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Code G | —36,652 at $0.00 | filing |
| 3 Jun 2026filed 4 Jun 2026 | KLRS Kalaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,000 at $0.00 | filing |
| 3 Jun 2026filed 4 Jun 2026 | KLRS Kalaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,000 at $0.00 | filing |
| 16 Apr 2026filed 20 Apr 2026 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Sold | $1.5M30,615 at $49.57 | filing |
| 16 Apr 2026filed 20 Apr 2026 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Sold | $1.5M30,615 at $49.57 | filing |
| 9 Feb 2026filed 11 Feb 2026 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Code A | —128,004 at $0.00 | filing |
| 9 Feb 2026filed 11 Feb 2026 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Code A | —128,004 at $0.00 | filing |
| 13 Jan 2026filed 15 Jan 2026 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Sold | $2.5M57,450 at $42.70 | filing |
| 13 Jan 2026filed 15 Jan 2026 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Sold | $2.5M57,450 at $42.70 | filing |
| 8 Oct 2025filed 9 Oct 2025 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Code G | —205,000 at $0.00 | filing |
| 29 Aug 2025filed 29 Aug 2025 | iTeos Therapeuticsoption or derivative | SEC FORM 4 Code D | —25,140 | filing |
| 29 Aug 2025filed 29 Aug 2025 | iTeos Therapeuticsoption or derivative | SEC FORM 4 Code D | —146,160 | filing |
| 6 Jun 2025filed 6 Jun 2025 | iTeos Therapeuticsoption or derivative | SEC FORM 4 Code M | —38,228 at $0.00 | filing |
| 6 Jun 2025filed 6 Jun 2025 | iTeos Therapeutics | SEC FORM 4 Code M | $164K38,228 at $4.30 | filing |
| 6 Jun 2025filed 6 Jun 2025 | iTeos Therapeutics | SEC FORM 4 Sold | $391K38,228 at $10.24 | filing |
| 5 Jun 2025filed 6 Jun 2025 | iTeos Therapeuticsoption or derivative | SEC FORM 4 Code M | —38,227 at $0.00 | filing |
| 5 Jun 2025filed 6 Jun 2025 | iTeos Therapeutics | SEC FORM 4 Code M | $164K38,227 at $4.30 | filing |
| 5 Jun 2025filed 6 Jun 2025 | iTeos Therapeutics | SEC FORM 4 Sold | $388K38,227 at $10.15 | filing |
| 4 Jun 2025filed 6 Jun 2025 | iTeos Therapeuticsoption or derivative | SEC FORM 4 Code M | —38,227 at $0.00 | filing |
News
Scholar Rock Resubmits Marketing Authorisation Application For ApitegromabSRRK · rttnews.com · 8 Oct 2026
0 headlines in the last 90 days name David Hallal; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.